News

GeneMatch designed to speed up Alzheimer’s trial recruitment


 

References

GeneMatch is not only an important research tool, Dr. Tariot said, but a way that anyone can take part in the search for an Alzheimer’s treatment.

“This process changes the role people can play in research. Families of patients often feel helpless after a diagnosis, but GeneMatch can give them the opportunity to take action, to be part of the movement to end this before another generation is lost.”

msullivan@frontlinemedcom.com

Pages

Recommended Reading

Raloxifene ineffective for treating AD patients
MDedge Family Medicine
High-risk patients fared best in lifestyle intervention trial for cognitive decline
MDedge Family Medicine
Omega-3 plus physical, mental training prevented cognitive decline for 3 years
MDedge Family Medicine
CTAD: Revived Alzheimer’s symptomatic drug set to test as donepezil combo
MDedge Family Medicine
CTAD: Sigma-1 receptor agonist passes muster in small Alzheimer’s trial
MDedge Family Medicine
CTAD: New aducanumab subanalysis bolsters phase III trials in very mild Alzheimer’s
MDedge Family Medicine
BRCA1 may have an impact in Alzheimer’s disease
MDedge Family Medicine
CTAD: Anti-tau vaccine demonstrated safety, immunogenicity in phase I study
MDedge Family Medicine
New analyses of data keep hope alive for Alzheimer’s drug gantenerumab
MDedge Family Medicine
ADT linked to increased risk of Alzheimer’s disease
MDedge Family Medicine